Table of Contents
- Trial overview
- Who is being studied
- Treatment plan in the trial
- What the trial measures
- Trial phase and size
- What patients should know
Trial overview
This article describes one authorised interventional study of ALLOGENEIC UMBILICAL CORD BLOOD-DERIVED NATURAL KILLER CELLS, EX VIVO EXPANDED given with rituximab in adults with relapsing forms of B-cell dependent rheumatologic diseases.[1] The study is designed to assess safety, tolerability, and early signs of benefit after lymphodepletion with cyclophosphamide and fludarabine.[1]
Who is being studied
The trial includes adult subjects with hard-to-treat rheumatic diseases.[1] The conditions listed are systemic sclerosis (SSc), rheumatoid arthritis (RA), idiopathic inflammatory myopathies (IIMs), and Sjögren’s disease (SjD).[1]
The study summary says these are relapsing forms of B-cell dependent rheumatologic diseases.[1] In simple terms, this means the diseases can flare up again after improvement, and the study focuses on illnesses where B cells are an important part of the disease process.[1]
Treatment plan in the trial
The study treatment is given with rituximab, and the trial also uses cyclophosphamide and fludarabine before the main study treatment.[1] This before-treatment step is called lymphodepletion, which means lowering certain immune cells first.[1]
The intervention list shows cyclophosphamide and fludarabine as intravenous infusions, rituximab as an intravenous infusion, and AB-101 as an intravenous treatment.[1] The source also names the study product as AlloNK®, which is the trial name used in the study summary.[1]
What the trial measures
The main safety goal is to find dose-limiting toxicities, meaning side effects that may stop the dose from being increased.[1] The trial uses a 3+3 design to help determine the MTD (maximum tolerated dose) and/or MAD (maximum administered dose).[1]
The main disease response measures are checked at Week 52.[1] For idiopathic inflammatory myopathies, the endpoint is TIS ≥ 60; for systemic sclerosis, it is rCRISS ≥ 50; for rheumatoid arthritis, it is DAS28-ESR < 2.6; and for Sjögren’s disease, it is an improvement of at least 4 points in ClinESSDAI from baseline.[1]
These scores are used to measure whether the disease is getting better.[1] They are different tools for different diseases, so the study can judge benefit in a way that matches each condition.[1]
Trial phase and size
This is a Phase 2 study.[1] Phase 2 trials usually look at both safety and early benefit in a group of patients who have the disease being studied.[1]
The planned enrollment is 92 participants.[1] The status is listed as authorised.[1]
What patients should know
This study is not a general review of the treatment; it is a clinical trial focused on a specific patient group with difficult rheumatic diseases.[1] The main question is whether the study approach can be given safely and whether it may help symptoms and disease activity.[1]
The trial uses several disease-specific outcome measures, which helps researchers look at benefit in a more precise way for each illness.[1] Based on the source data, the study is centered on adult patients with relapsing B-cell dependent rheumatologic disease rather than on healthy volunteers.[1]
